gatifloxacin has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of hypoglycemia in a patient receiving gatifloxacin for presumed exacerbation of chronic obstructive pulmonary disease (COPD)." | 7.71 | Possible gatifloxacin-induced hypoglycemia. ( Baker, SE; Hangii, MC, 2002) |
| "Gatifloxacin was generally well tolerated, and the majority of adverse events were mild to moderate; only 11 drug-related adverse events in 10 patients (0." | 5.31 | Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. ( Anzueto, A; Gotfried, M; Nicholson, SC; Russo, R; Wikler, MA, 2002) |
| "To report a case of hypoglycemia in a patient receiving gatifloxacin for presumed exacerbation of chronic obstructive pulmonary disease (COPD)." | 3.71 | Possible gatifloxacin-induced hypoglycemia. ( Baker, SE; Hangii, MC, 2002) |
| "Gatifloxacin was generally well tolerated, and the majority of adverse events were mild to moderate; only 11 drug-related adverse events in 10 patients (0." | 1.31 | Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. ( Anzueto, A; Gotfried, M; Nicholson, SC; Russo, R; Wikler, MA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzueto, A | 1 |
| Gotfried, M | 1 |
| Wikler, MA | 1 |
| Russo, R | 1 |
| Nicholson, SC | 1 |
| Baker, SE | 1 |
| Hangii, MC | 1 |
2 other studies available for gatifloxacin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis, Chronic; Female; Fluoroquinolones | 2002 |
Possible gatifloxacin-induced hypoglycemia.
Topics: Aged; Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Humans; Hypoglycemia; Male; Pulmonary D | 2002 |